Fierce Pharma
APRIL 4, 2024
Amylyx Pharmaceuticals is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. | Amylyx is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. And 70% of the company's staff will soon lose their jobs.
MedCity News
APRIL 4, 2024
Quantum Health CEO Zane Burke and Imagine360 CEO Jeff Bak highlighted the significance of the partnership, what it means for their respective businesses, and the industry at large, in response to emailed questions. The post Ardent Health Opts for New Employee Benefits and Employee Experience with Quantum Health and Imagine360 appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
APRIL 4, 2024
With a new order clarifying several terms of the patents at the center of Arbutus Biopharma and Genevant Sciences’ infringement suit against Moderna, the companies are one step closer in | A Delaware judge sided with Arbutus and Genevant's proposed constructions of the patent claims in question, strengthening their case against Moderna and its COVID-19 vaccine Spikevax.
MedCity News
APRIL 4, 2024
LLMs bring great potential to help the healthcare industry center care around patients’ needs by improving communication, access, and engagement. However, LLMs also present significant challenges associated with privacy and bias that also must be considered. The post How Large Language Models Will Improve the Patient Experience appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
APRIL 4, 2024
As Teva advances its Pivot to Growth strategy under CEO Richard Francis, the company is making good on its pledge to beef up its biosimilar pipeline through outside deals. | Teva has unveiled a fresh in-licensing accord with Spain’s mAbxience to chip in on an investigational biosimilar spanning multiple oncology indications. Under the deal, Teva will oversee regulatory duties and marketing for the biosimilar, while mAbxience is on the hook to continue developing and manufacturing the drug at its
pharmaphorum
APRIL 4, 2024
President Joe Biden has reiterated his pledge to take action against high drug prices and “beat big pharma,” singling out the cost of asthma inhalers in a speech delivered at a White House event with US Senator Bernie Sanders, a long-time critic of the industry’s pricing policies in the US.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
APRIL 4, 2024
Implementing diverse and sustained strategies to empower frontline workers should be the cornerstone of any modern healthcare workforce management program. The post Frontline Burnout in Healthcare: A Growing Crisis Demands Action appeared first on MedCity News.
Fierce Pharma
APRIL 4, 2024
Fifteen years after Basilea's antibiotic ceftobiprole sustained a rejection from the FDA, the company has finally won over the U.S. regulator and done so in triplicate. | Fifteen years after Basilea's antibiotic ceftobiprole sustained a rejection from the FDA, the company has finally won over the U.S. regulator and done so in triplicate. The FDA has approved Basilea’s Zevtera for three different kinds of infections.
MedCity News
APRIL 4, 2024
The MedCity INVEST conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago. In addition to panel discussions around some of the hottest topics in healthcare transformation, there is also a startup pitch contest, a presentation on government funding for startups and networking opportunities. The post Boutique Healthcare Investment Event in Chicago Highlights AI, Government Funding, Value-Based Care.
Fierce Pharma
APRIL 4, 2024
Sanofi has agreed to settle approximately 4,000 personal injury claims from users of its heartburn drug Zantac, resolving litigation in all U.S. | Sanofi has agreed to settle approximately 4,000 personal injury claims from users of its heartburn drug Zantac, resolving litigation in all U.S. state courts besides Delaware, the company confirmed on Thursday.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
APRIL 4, 2024
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug class.
Fierce Pharma
APRIL 4, 2024
Sanofi pledges to keep polio vaccine supplies afloat in India after new approval fkansteiner Thu, 04/04/2024 - 16:04
pharmaphorum
APRIL 4, 2024
Healthcare system Providence has spun out a new company, Praia Health, focused on a platform to build and sustain connections between patients and health providers. The new company starts life with $20 million in Series A funding and a mission to develop the Praia Health Identity and Engagement Platform, which was launched within Providence’s digital innovation group (DIG) incubator in 2022 and already handles around 3.5 million user accounts.
Fierce Pharma
APRIL 4, 2024
Fierce Pharma Asia—Eisai's subQ Leqembi delay; Legend and J&J's supply deal with Novartis; China's Ozempic biosimilar aliu Thu, 04/04/2024 - 16:14
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
APRIL 4, 2024
Employers are struggling with point solution fatigue, but does that mean new startups shouldn’t be selling to them anymore? Experts have mixed opinions. The post Should New Entrants Bother With Selling Point Solutions To Employers? appeared first on MedCity News.
Eversana Intouch
APRIL 4, 2024
MM+M recently named Teva Pharmaceuticals’ AUSTEDO XR campaign as their Campaign of the Week! AUSTEDO XR helps treat tardive dyskinesia (TD), a side effect of taking medications for mental illness. It’s estimated that some 85% of TD cases go undiagnosed. To help patients and HCPs recognize TD, our team partnered with Teva on two new TV spots focusing on two different journeys of characters who have TD.
MedCity News
APRIL 4, 2024
Chicago-based Prenosis gained FDA clearance for its sepsis detection technology this week, marking the first time the agency has cleared an AI diagnostic tool for sepsis. The post FDA Grants Its First-Ever Clearance for Sepsis Detection AI appeared first on MedCity News.
Pharmaceutical Commerce
APRIL 4, 2024
The latest news for pharma industry insiders.
European Pharmaceutical Review
APRIL 4, 2024
A new £17.9 million initiative announced on 21 March is set to accelerate advanced therapy development in the UK. The scheme aims to support UK advanced therapy medicinal product (ATMP) clinical trials. UK Health Minister Andrew Stephenson commented on the news, stating that the investment “reaffirms the UK’s position as a global leader in clinical research”.
PharmaTimes
APRIL 4, 2024
The fatal, progressive neurological condition currently affects around 5,000 people in the UK
European Pharmaceutical Review
APRIL 4, 2024
US radiopharmacy network RLS Radiopharmacies is expanding its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by establishing a partnership with global isotope technology company Eckert & Ziegler. As part of the agreement, all 31 of RLS’ radiopharmacies will be produce Gallium-68-based (Ga-68) radiopharmaceuticals by the end of June, the company confirmed.
PharmaTimes
APRIL 4, 2024
The project will assist researchers and companies in training the technology for healthcare settings
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
European Pharmaceutical Review
APRIL 4, 2024
The European Commission (EC) has expanded the approval of Reblozyl ® (luspatercept) to include the first-line treatment of adults with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS ). This indication expansion of Reblozyl covers all EU member states, excluding Great Britain. Bristol Myers Squibb stated that this makes it the fourth authorised indication in Europe for Reblozyl.
MedCity News
APRIL 4, 2024
The voluntary removal of ALS drug Relyvrio from the market comes with a corporate restructuring that turns Amylyx Pharmaceuticals’ focus to other neurodegenerative diseases. But the company also has another ALS drug candidate set to begin clinical testing this year. The post Amylyx Withdraws ALS Drug From Market; Restructuring Will Slash 70% of Staff appeared first on MedCity News.
pharmaphorum
APRIL 4, 2024
Researchers in the UK will soon start trialling blood tests that promise to diagnose dementia at clinics across the country in the hope of having them in routine NHS use within five years. Two teams from University College London and the University of Oxford are spearheading a pair of studies that will recruit around 5,000 volunteers at more than 50 memory clinics in the UK.
Pharmaceutical Technology
APRIL 4, 2024
Discover how F. Hoffmann-La Roche's patented system uses nanopores to identify nucleic acid bases, increasing confidence in base identification. Explore the innovative approach in genomics and personalized medicine.
PharmaVoice
APRIL 4, 2024
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
PharmExec
APRIL 4, 2024
Early results have demonstrated that mRNA-3927 has led to a 70% reduction in the relative risk for metabolic decompensation events in patients with propionic acidemia.
Pharmaceutical Technology
APRIL 4, 2024
Discover Chiesi Farmaceutici's innovative patent for a specialized pharmaceutical formulation aimed at enhancing drug delivery efficiency for Parkinson's disease treatment. Learn about the unique composition and processes involved in this groundbreaking intraduodenal administration solution.
Pharmaceutical Commerce
APRIL 4, 2024
Year-on-year growth in demand is strong, according to the IATA.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
306 
Let's personalize your content